Last reviewed · How we verify

NCT02713334

Cancer Patients Decision Making and Family Communication About Secondary Findings From Tumor Genomic Profiling

Active, enrolled Last updated 11 July 2025
What this trial tests

trial testing survey in Tumor Genomic Profiling in 495 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline
25 February 2016
Primary endpoint
25 February 2026
25 February 2026

Quick facts

Lead sponsorMemorial Sloan Kettering Cancer Center
StatusActive, enrolled
Study typeOBSERVATIONAL
Enrollment495
Start date25 February 2016
Primary completion25 February 2026
Estimated completion25 February 2026
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

Memorial Sloan Kettering Cancer Center — full company profile →

Who can join

18 and older, any sex, with Tumor Genomic Profiling. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The objective of this protocol is to characterize cancer patients' responses to learning their secondary findings arising from tumor genomic profiling, and the process and outcomes of their decisions to communicate these results to their families.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of survey

Trials testing the same drug.

Other Memorial Sloan Kettering Cancer Center trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02713334.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing